TrueWealth LLC’s Esperion Therapeutics ESPR Stock Holding History

TrueWealth LLC’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$8K	Hold	162	–	–	﹤0.01%	498
2020 Q1	$5K	Buy	+162	New	+$8.55K	﹤0.01%	547

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

TrueWealth LLC's ESPR Position: Q2 2020 in Review

TrueWealth LLC held its Esperion Therapeutics (ESPR) position steady in Q2 2020 at 162 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #498.

TrueWealth LLC first reported a position in ESPR in Q1 2020 and has held it in 2 quarters since. 183 funds tracked by Wall St. Rank hold ESPR as of Q2 2020.

TrueWealth LLC held 162 shares of Esperion Therapeutics worth $8K as of Q2 2020.
TrueWealth LLC left its Esperion Therapeutics share count unchanged in Q2 2020.
Esperion Therapeutics made up ﹤0.01% of TrueWealth LLC's portfolio in Q2 2020, its #498 holding.
TrueWealth LLC first reported a position in Esperion Therapeutics in Q1 2020 and has held it in 2 quarters since.
183 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2020.

Based on TrueWealth LLC's 13F filing for Q2 2020, filed 15 Jul 2020.